秒速时时彩

Characteristic raw material drug production center upgrading project environmental impact assessment public participation first publicity content

Published in: 05 2019, 06, published: Stone Pharmaceutical Group


1. Project name: upgrading project of characteristic API production center.

2. Project overview

Ouyi Pharmaceutical Co., Ltd. of Shijiazhuang Pharmaceutical Co., Ltd. has made up and upgraded the production line of Asif, including the production line of the center for the upgrading of raw materials, the production line of A Lun methanone, the sodium phosphonate, the production line of maleic acid amlodipine, the production line of solvent recovery and the production line of traditional Chinese medicine, and the addition of 43 sets of main technology and equipment. After the completion of the project, according to the market demand, the collinear product flexible production mode was adopted, and indomethacin, nitrendipine and vitamin production capacity were added on the basis of Asif Mei Xin production line. Indomethacin had the largest annual production capacity of 17t/a, Nissan's annual maximum production capacity of 90t/a, vitamin BT maximum production capacity of 12t/a, and the addition of alendronate and amlodipine maleate production line. Ranitidine hydrochloride, ambroxol hydrochloride and Clopidogrel Hydrogen Sulfate capacity, among them, ranitidine hydrochloride has the largest production capacity of 35t/a, ambroxol hydrochloride maximum capacity 35t/a, hydrochloric acid clopidogrel maximum capacity 12t/a; optimize the existing AKI workshop matching solvent recovery technology for methyl benzosulfonic acid, new petroleum ether recovery process, achieve p-toluene sulfonyl chloride recovery capacity 200t/a.

On the basis of the existing Chinese medicine production line, there are 7 new Chinese herbal medicine production lines, including the maximum production capacity of 42t/a, the maximum production capacity of 66t/a, the maximum production capacity of 210t/a, the maximum production capacity of 150t/a, the maximum yield of 18t/a, the maximum yield of 69t/a, and the maximum capacity of Isatis indigotica extract 90t/a. A traditional Chinese medicine production line is used for formula granule production, and the maximum production capacity of formula granules is 280t/a. The total investment is 40 million yuan.

3, construction units and contact ways

Construction unit: Ouyi Pharmaceutical Co., Ltd.

Contact: Li Shaofang

Li Shaofang Tel: 15393095532

4. The name of the compilation of environmental impact statement.

Hebei Qi Zheng Environment Technology Co., Ltd.

5, the main matter of soliciting public opinions

In order to listen to the opinions and suggestions from all sectors of the society on the environmental protection of the upgrading project of the special drug production center, we will publicized the project and ask the public for valuable ideas and suggestions. The content of non environmental protection is not within the scope of this solicitation.

6, the main way of public opinion.

From now on, the public may send a letter to the designated address of the public address (delivery address: No. 88 Yangzi Road, Shijiazhuang economic and Technological Development Zone, Tel: 15393095532: recipient: Li Shaofang), or other ways provided by the construction unit, and publish the opinions and opinions on the project construction and EIA within the prescribed time. Name to facilitate timely response to your comments.

Public opinion list network link

Links: Https://pan.baidu.com/s/1iKKMbXBzUlK9IRLZJfz5BQ

7, public notice start and stop time

From May 6, 2019 to May 17, 2019.

Ouyi Pharmaceutical Co., Ltd.

May 6, 2019